$ACT Company News Icahn Enterprises reports profit up

New Post Public Reply Private Reply Replies (0) Message Board

Mar 4, 2014 at 10:57 AM

$ACT Company News

Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Investors drive up price of Actavis-Forest deal 11:14 a.m. Feb. 18, 2014 - blogs.marketwatch.com
Actavis shares jump 7.8% on Forest Lab deal 9:35 a.m. Feb. 18, 2014 - Sue Chang
U.S. stock futures trim rise; Forest Labs soars 9:14 a.m. Feb. 18, 2014 - Sara Sjolin
Actavis-Forest Labs is play on changes in health care 9:06 a.m. Feb. 18, 2014 - Dana Mattioli
Actavis confirms $25 bln Forest Labs acquistion 7:15 a.m. Feb. 18, 2014 - Sara Sjolin
Actavis shares climb 10% on deal for Forest Labs 7:12 a.m. Feb. 18, 2014 - Silvia Ascarelli
Forest Lab surges 27% premarket on Actavis deal 7:09 a.m. Feb. 18, 2014 - Silvia Ascarelli

Pernix to Market Osmotica's Khedezla - Analyst Blog 5:30 p.m. March 3, 2014 - Zacks.com
Actavis Challenges Patents - Analyst Blog 4:45 p.m. March 3, 2014 - Zacks.com
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog 1:26 p.m. March 3, 2014 - Zacks.com
Biogen Idec Keeps Momentum Going With MS Drug Tecfidera 1:05 p.m. March 3, 2014 - Investors Business Daily
One Hardworking Bull 1:55 a.m. March 1, 2014 - Barrons.com
Actavis PLC (ACT): Today's Featured Health Care Laggard 5:01 p.m. Feb. 28, 2014 - TheStreet.com
Seattle Genetics Presents Data on Adcetris - Analyst Blog 3:17 p.m. Feb. 28, 2014 - Zacks.com
Patent Update from Mallinckrodt - Analyst Blog 5:20 p.m. Feb. 27, 2014 - Zacks.com
Valeant Beats Q4 Estimates, Talks Buyout Strategy 4:38 p.m. Feb. 27, 2014 - Investors Business Daily
Can The Uptrend Continue for Actavis (ACT)? - Tale of the Tape 9:47 a.m. Feb. 27, 2014 - Zacks.com
Enter Biosimilars: 3 Stock Picks - Analyst Blog 1:13 p.m. Feb. 26, 2014 - Zacks.com
Wider-than-Expected Loss at Pacira - Analyst Blog 12:20 p.m. Feb. 26, 2014 - Zacks.com
Weakness Seen in Tenet Healthcare (THC): Stock Tumbles 9.1% - Tale of the Tape 8:56 a.m. Feb. 26, 2014 - Zacks.com
Market Hits New High, 3 Stocks To Consider 8:22 p.m. Feb. 25, 2014 - Seeking Alpha
Update on Teva's DuoResp Spiromax - Analyst Blog 6:00 p.m. Feb. 25, 2014 - Zacks.com
3 Stocks Pushing The Health Care Sector Higher 12:02 p.m. Feb. 25, 2014 - TheStreet.com
New Lifetime High Reached By Actavis (ACT) 9:45 a.m. Feb. 25, 2014 - TheStreet.com
Akorn (AKRX) in Focus: Stock Moves 5.0% Higher - Tale of the Tape 9:21 a.m. Feb. 25, 2014 - Zacks.com
10-K: ACTAVIS PLC 9:04 a.m. Feb. 25, 2014 - Edgar Online - (EDG = 10Q, 10K)
Mr. Market Loves Jazz Pharmaceuticals, Time To Sell 3:47 a.m. Feb. 25, 2014 - Seeking Alpha

Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. Today - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Actavis to Present at Citi's 2014 Global Healthcare Conference 4:25 p.m. Feb. 19, 2014 - PR Newswire - PRF
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver 9:31 a.m. Feb. 19, 2014 - PR Newswire - PRF
Actavis to buy Forest Labs for $25B and GT Advanced Tech acquires exclusive rights from Kyma Tech 12:31 a.m. Feb. 19, 2014 - ACCESSWIRE
Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests 9:02 p.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Cancel Q4 and FY 2013 Earnings Call Previously Scheduled for Thursday, February 20, 2014 5:13 p.m. Feb. 18, 2014 - PR Newswire - PRF
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Forest Laboratories, Inc. Stockholders 5:01 p.m. Feb. 18, 2014 - BusinessWire - BZX
Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable 2:52 p.m. Feb. 18, 2014 - BusinessWire - BZX
FOREST SHAREHOLDERS NOTICE:Johnson & Weaver, LLP Announces Investigation of the Forest Laboratories, Inc. Proposed Acquisition by Actavis plc 9:43 a.m. Feb. 18, 2014 - BusinessWire - BZX
INVESTOR BUYOUT ALERT - Offer to Acquire Forest Laboratories - Shareholder Rights Law Firm Tripp Levy PLLC Seeks Higher Price And More Information For Shareholders 8:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Host Fourth Quarter 2013 Earnings Conference Call and Webcast 8:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Treanda® Patent Challenge 8:00 a.m. Feb. 4, 2014 - PR Newswire - PRF
Actavis Presents Outlook for Continued Long-Term Growth 7:15 a.m. Jan. 31, 2014 - PR Newswire - PRF
Actavis Announces Refocused Global Business Structure to Maximize Evolution into Global Specialty Pharmaceuticals Leadership 7:00 a.m. Jan. 31, 2014 - PR Newswire - PRF
Actavis Announces Agreement with Zhejiang Chiral Medicine Chemicals Co., Ltd to Divest Actavis Foshan, China 4:05 p.m. Jan. 24, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Infotech's 2026 Report Crowns PSA Software Leaders

Spotlight on PSA Trailblazers It's 2026, and Infotech has dropped its latest bombshell—the Professional Services Automation Data Quadrant Report. This ain't just your run-of-the-mill software rankings; it's a peek into tools that could make or break project management for service-oriented businesses. Five top dogs, RocketLane, Wrike, Accelo, SAP Professional Services...

NORROY's Radiopharma Innovations: EANM Highlights

Breaking Ground: NORROY's Radiopharmaceutical Innovations If you thought the radiopharmaceutical game was stuck in the same ol' rut, NORROY Bioscience just flipped the script. Standing out at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26) in Vienna, they trotted out enough breakthroughs to make you wonder if they're secretly running on...

AlphaESS Secures Fifth Tier 1 Status Amid Growth

AlphaESS: Consistency Breeds Success Can't ignore a company that keeps hitting the marks quarter after quarter, kid. AlphaESS just bagged its fifth consecutive Tier 1 status from BloombergNEF for Q4 2026—that's no joke in the buzzing world of energy storage. What makes this outfit tick? It's not just sticking to the same old script; they keep leveling up while everyone...

GomSpace Eyes SEK 1.6 Billion Revenue by 2030

Cracking Open GomSpace's Q3 Gains You don't just stumble upon profitability in this market; that's for sure. GomSpace, however, seems to have a knack for finding its stride amidst the chaos. In their latest earnings report, it looks like they're not just coasting—they're powering through with profitable growth in the third quarter. Who would have thought? These folks...

Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

KT&G Soars with Record Profits, Aggressive Share Buybacks

KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....

SKF's Industrial Push: Energy Efficiency at COP31

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Magnolia Data Breach: Legal Stakes Loom for Seniors

Elderly Residents at Risk After Data Breach Well, here we go again — another day, another data breach debacle. This time, it's Magnolia Management putting senior residents' sensitive information on a silver platter for potential cyber intruders. We're talking names, Social Security numbers, and medical records — the whole shebang. When you're handling such crucial...

Multi-Society Panel Boosts Vaccine Guidance Clarity

Vaccination Confusion: Could Clarity Finally Be Here? Here's the scoop, folks. In the swirling mess of immunization advice, a coalition of top medical societies has thrown a lifeline to clinicians. If you're drowning in conflicting vaccine guidance, this panel's unified stance might just be your life raft. The Coalition Forces of Immunization We have the Vaccine Guidance...

Bram Schot Steers Marelli Through Chapter 11 Resurgence

So, Marelli's rolling out the heavy artillery with the appointment of Bram Schot as their future Chair. This isn't just reshuffling a few chairs on the deck of a wobbly ship. No, Marelli's emergence from Chapter 11, with Schot at the helm, is more akin to a full-blown course correction. The man comes seasoned, having braved the corporate gales at Audi, Mercedes-Benz, and...